BRPI0412231A - derivados de pentanol substituìdos heterociclicamente, processos para a sua preparação e sua aplicação como inibidores de inflamação - Google Patents

derivados de pentanol substituìdos heterociclicamente, processos para a sua preparação e sua aplicação como inibidores de inflamação

Info

Publication number
BRPI0412231A
BRPI0412231A BRPI0412231-3A BRPI0412231A BRPI0412231A BR PI0412231 A BRPI0412231 A BR PI0412231A BR PI0412231 A BRPI0412231 A BR PI0412231A BR PI0412231 A BRPI0412231 A BR PI0412231A
Authority
BR
Brazil
Prior art keywords
preparation
application
processes
derivatives
inflammation inhibitors
Prior art date
Application number
BRPI0412231-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Markus Berger
Stefan Bourle
Hartmut Rehwinkel
Norbert Schmees
Heike Schocke
Manfred Lehmann
Konrad Krolikiewicz
Arndt J B Schottelius
Duy Nguyen
Anne Mengel
Stefan Jaroch
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2003130358 external-priority patent/DE10330358A1/de
Priority claimed from DE2003146939 external-priority patent/DE10346939A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0412231A publication Critical patent/BRPI0412231A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
BRPI0412231-3A 2003-07-01 2004-06-22 derivados de pentanol substituìdos heterociclicamente, processos para a sua preparação e sua aplicação como inibidores de inflamação BRPI0412231A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2003130358 DE10330358A1 (de) 2003-07-01 2003-07-01 Heterozyklisch substituierte Pentanol-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE2003146939 DE10346939A1 (de) 2003-10-06 2003-10-06 Heterocyclisch substituierte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
PCT/EP2004/006765 WO2005003098A1 (de) 2003-07-01 2004-06-22 Heterozyklisch substituierte pentanol-derivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer

Publications (1)

Publication Number Publication Date
BRPI0412231A true BRPI0412231A (pt) 2006-08-22

Family

ID=33566017

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412231-3A BRPI0412231A (pt) 2003-07-01 2004-06-22 derivados de pentanol substituìdos heterociclicamente, processos para a sua preparação e sua aplicação como inibidores de inflamação

Country Status (13)

Country Link
EP (1) EP1638945A1 (es)
JP (1) JP2008529963A (es)
KR (1) KR20060027376A (es)
AU (1) AU2004254205A1 (es)
BR (1) BRPI0412231A (es)
CA (1) CA2531060A1 (es)
EA (1) EA200600148A1 (es)
EC (1) ECSP066329A (es)
IL (1) IL172899A0 (es)
MX (1) MXPA06000169A (es)
NO (1) NO20060534L (es)
RS (1) RS20050974A (es)
WO (1) WO2005003098A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
DE502004002403D1 (de) 2003-10-08 2007-02-01 Schering Ag Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US8093281B2 (en) 2005-04-14 2012-01-10 Glaxo Group Limited Indazoles as glucocorticoid receptor ligands
DE102005030293A1 (de) * 2005-06-24 2007-01-04 Schering Ag Verwendung von nichtsteroidale Progesteronrezeptor-Modulatoren
DE102005030292A1 (de) * 2005-06-24 2007-01-11 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
GB0522880D0 (en) * 2005-11-09 2005-12-21 Glaxo Group Ltd Novel compounds
EP1834948A1 (de) 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
KR20090003349A (ko) * 2006-04-20 2009-01-09 글락소 그룹 리미티드 화합물
EP1878717A1 (en) * 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
GB0620406D0 (en) * 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
GB0620385D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
WO2008055709A1 (en) * 2006-11-08 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Indazole and indole derivatives as anti -inflammatory agents
EP1921067A1 (en) * 2006-11-08 2008-05-14 Bayer Schering Pharma Aktiengesellschaft Indole and indazole derivatives as anti-inflammatory agents
EP1921068A1 (en) * 2006-11-08 2008-05-14 Bayer Schering Pharma Aktiengesellschaft Indazole and indole derivatives as anti-inflammatory agents
WO2008060799A2 (en) * 2006-11-09 2008-05-22 Bausch & Lomb Incorporated Synthesis of selected stereoisomers of certain substituted alcohols
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
GB0720549D0 (en) * 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720544D0 (en) * 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720556D0 (en) * 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
EP2062880A1 (en) 2007-11-22 2009-05-27 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
WO2009069736A1 (ja) * 2007-11-28 2009-06-04 Kyowa Hakko Kirin Co., Ltd. 含窒素化合物
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
EA019441B1 (ru) 2008-12-30 2014-03-31 Палмаджен Терепьютикс (Инфлеммейшн) Лимитед Сульфонамиды, предназначенные для лечения респираторных нарушений
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
DE10038639A1 (de) * 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
ES2276038T3 (es) * 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
DE10215316C1 (de) * 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer

Also Published As

Publication number Publication date
WO2005003098A1 (de) 2005-01-13
MXPA06000169A (es) 2006-04-27
NO20060534L (no) 2006-04-03
CA2531060A1 (en) 2005-01-13
WO2005003098B1 (de) 2005-03-03
KR20060027376A (ko) 2006-03-27
IL172899A0 (en) 2006-06-11
RS20050974A (en) 2007-09-21
AU2004254205A1 (en) 2005-01-13
EP1638945A1 (de) 2006-03-29
EA200600148A1 (ru) 2006-08-25
JP2008529963A (ja) 2008-08-07
ECSP066329A (es) 2006-07-28

Similar Documents

Publication Publication Date Title
BRPI0412231A (pt) derivados de pentanol substituìdos heterociclicamente, processos para a sua preparação e sua aplicação como inibidores de inflamação
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
MXPA04004301A (es) Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
EA200702058A1 (ru) Новые фармацевтические соединения
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
MA31167B1 (fr) Inhibiteurs de l'activite de akt
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
ATE544761T1 (de) Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
RS52700B (en) SUBSTITUTED OXINDOL DERIVATIVE AND ITS USE AS A VASOPRESIN RECEPTOR LIGAND
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
DE602005010970D1 (de) Indol-derivate und ihre verwendung als kinase-hemmer, insbesondere ikk2-hemmer
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
NO20052858L (no) Nye tricykliske forbindelser som LTD4-antagonister
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
HRP20050382A2 (en) Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.